Oxford Nanopore Technologies PLC ONTTF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $1.20
- Day Range
- $1.25–1.26
- 52-Week Range
- $1.13–3.52
- Bid/Ask
- $1.21 / $1.27
- Market Cap
- $1.07 Bil
- Volume/Avg
- 1,462 / 24,505
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 4.75
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Oxford Nanopore Technologies PLC makes a novel generation of DNA/RNA sequencing technology that provides rich data and is fast, accessible, and easy to use. The Group is primarily involved in researching, developing, manufacturing, and commercializing the world’s only commercial nanopore-based sequencing platform that allows the real-time analysis of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA). This enables our customers to perform scientific/biomedical research in a range of areas, including human genetics, cancer research, outbreak surveillance, environmental analysis, pathogens/antimicrobial resistance, microbiome analysis, and crop science.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 1,133
- Website
- https://www.nanoporetech.com
Comparables
Valuation
|
Metric
|
ONTTF
|
EXAS
|
300396
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 21.96 |
Price/Book Value | 1.84 | 3.39 | 3.13 |
Price/Sales | 4.75 | 4.24 | 3.94 |
Price/Cash Flow | — | 67.76 | 145.23 |
Price/Earnings
ONTTF
EXAS
300396
Financial Strength
|
Metric
|
ONTTF
|
EXAS
|
300396
|
|---|---|---|---|
Quick Ratio | 4.85 | 1.91 | 1.29 |
Current Ratio | 6.00 | 2.32 | 1.88 |
Interest Coverage | −65.91 | −7.26 | 37.85 |
Quick Ratio
ONTTF
EXAS
300396
Profitability
|
Metric
|
ONTTF
|
EXAS
|
300396
|
|---|---|---|---|
Return on Assets (Normalized) | −16.17% | −0.51% | 9.79% |
Return on Equity (Normalized) | −25.13% | −1.05% | 14.94% |
Return on Invested Capital (Normalized) | −19.39% | −0.23% | 12.01% |
Return on Assets
ONTTF
EXAS
300396
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Gwzpwrcbx | Zdnx | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Tjlxssb | Lwjgbk | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Jksjpkc | Xzjmdn | $97.8 Bil | |
MRNA
| Moderna Inc | Vsvsjqh | Pzbb | $41.3 Bil | |
ARGX
| argenx SE ADR | Ntpzpxfs | Dhqz | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Mlmscbmyf | Dlxv | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Hjwvgkhf | Lzzczck | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Hdxzydd | Kppnv | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Rzclbdhxw | Cgybjp | $12.5 Bil | |
INCY
| Incyte Corp | Lpdphbzx | Nchfst | $11.6 Bil |